Limits...
The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy.

Patel L, Thaker A - J Pharmacol Pharmacother (2015 Jul-Sep)

Bottom Line: The analysis of mRNA expression of A2B receptor and VEGF was performed.The effects of A2B AR modulators were prominent in CsA-treated animals compared with control animals suggesting CsA treatment may upregulate A2B ARs.The mRNA expression of A2B AR was increased after 5 weeks of CsA.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Anand, Gujarat, India.

ABSTRACT

Introduction: To investigate the actions of adenosine A2B receptor modulators on VEGF and NO levels in CsA nephropathy.

Materials and methods: Nephropathy was induced by administrating 25 mg/kg (s.c) of CsA for 5 weeks. The VEGF and NO levels were measured in kidney tissue. Serum creatinine, creatinine clearance, urinary albumin excretion, blood urea nitrogen, kidney pathology score were measured to assess renal function. The analysis of mRNA expression of A2B receptor and VEGF was performed.

Results: Administration of CsA for 5 weeks induced adverse renal function. The mRNA expression of VEGF was reduced in renal tissue after 5 weeks of CsA treatment. The renal VEGF and NO levels were also reduced in these animals. In vivo administration of A2B adenosine receptor agonist increased renal VEGF which was inhibited by a selective A2B AR antagonist (MRS1754) in CsA-treated animals. The increase in VEGF was associated with reversal of adverse renal functions. The effects of A2B AR modulators were prominent in CsA-treated animals compared with control animals suggesting CsA treatment may upregulate A2B ARs. The mRNA expression of A2B AR was increased after 5 weeks of CsA.

Conclusions: A2B AR modulators may provide new therapeutic options to retard CsA nephropathy by mediating renal VEGF and NO.

No MeSH data available.


Related in: MedlinePlus

Effect of adenosine receptor modulators on (a) VEGF mRNA and (b) kidney tissue VEGF levels in control and CsA-treated animals. Data are means (±sem) *P < 0.05 vs. control group, #P < 0.05 vs. CsA group, **P < 0.05 vs. CsA + NECA group, ##P < 0.05 vs. control NECA group, n = 6
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4544136&req=5

Figure 2: Effect of adenosine receptor modulators on (a) VEGF mRNA and (b) kidney tissue VEGF levels in control and CsA-treated animals. Data are means (±sem) *P < 0.05 vs. control group, #P < 0.05 vs. CsA group, **P < 0.05 vs. CsA + NECA group, ##P < 0.05 vs. control NECA group, n = 6

Mentions: To evaluate the impact of CsA on the expression level of VEGF in mice kidney, we examined mRNA levels in kidneys of control and CsA-treated animals. The changes in mRNA level were evaluated based on results from real-time PCR performed on cDNA transcribed from total RNA isolated from whole kidney. There was a significant reduction in the mRNA level of VEGF in kidney, 5 weeks after cyclosporine administration [Figure 2a]. Administration of NECA for 2 weeks raised the mRNA expression of VEGF in CsA-treated animals significantly, compared with control animals wherein, a partial increase was observed. The increase in VEGF mRNA expression by NECA was blocked by the treatment of MRS1754.


The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy.

Patel L, Thaker A - J Pharmacol Pharmacother (2015 Jul-Sep)

Effect of adenosine receptor modulators on (a) VEGF mRNA and (b) kidney tissue VEGF levels in control and CsA-treated animals. Data are means (±sem) *P < 0.05 vs. control group, #P < 0.05 vs. CsA group, **P < 0.05 vs. CsA + NECA group, ##P < 0.05 vs. control NECA group, n = 6
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4544136&req=5

Figure 2: Effect of adenosine receptor modulators on (a) VEGF mRNA and (b) kidney tissue VEGF levels in control and CsA-treated animals. Data are means (±sem) *P < 0.05 vs. control group, #P < 0.05 vs. CsA group, **P < 0.05 vs. CsA + NECA group, ##P < 0.05 vs. control NECA group, n = 6
Mentions: To evaluate the impact of CsA on the expression level of VEGF in mice kidney, we examined mRNA levels in kidneys of control and CsA-treated animals. The changes in mRNA level were evaluated based on results from real-time PCR performed on cDNA transcribed from total RNA isolated from whole kidney. There was a significant reduction in the mRNA level of VEGF in kidney, 5 weeks after cyclosporine administration [Figure 2a]. Administration of NECA for 2 weeks raised the mRNA expression of VEGF in CsA-treated animals significantly, compared with control animals wherein, a partial increase was observed. The increase in VEGF mRNA expression by NECA was blocked by the treatment of MRS1754.

Bottom Line: The analysis of mRNA expression of A2B receptor and VEGF was performed.The effects of A2B AR modulators were prominent in CsA-treated animals compared with control animals suggesting CsA treatment may upregulate A2B ARs.The mRNA expression of A2B AR was increased after 5 weeks of CsA.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Anand, Gujarat, India.

ABSTRACT

Introduction: To investigate the actions of adenosine A2B receptor modulators on VEGF and NO levels in CsA nephropathy.

Materials and methods: Nephropathy was induced by administrating 25 mg/kg (s.c) of CsA for 5 weeks. The VEGF and NO levels were measured in kidney tissue. Serum creatinine, creatinine clearance, urinary albumin excretion, blood urea nitrogen, kidney pathology score were measured to assess renal function. The analysis of mRNA expression of A2B receptor and VEGF was performed.

Results: Administration of CsA for 5 weeks induced adverse renal function. The mRNA expression of VEGF was reduced in renal tissue after 5 weeks of CsA treatment. The renal VEGF and NO levels were also reduced in these animals. In vivo administration of A2B adenosine receptor agonist increased renal VEGF which was inhibited by a selective A2B AR antagonist (MRS1754) in CsA-treated animals. The increase in VEGF was associated with reversal of adverse renal functions. The effects of A2B AR modulators were prominent in CsA-treated animals compared with control animals suggesting CsA treatment may upregulate A2B ARs. The mRNA expression of A2B AR was increased after 5 weeks of CsA.

Conclusions: A2B AR modulators may provide new therapeutic options to retard CsA nephropathy by mediating renal VEGF and NO.

No MeSH data available.


Related in: MedlinePlus